Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach

M. Fiorentino, E. Gruppioni, F. Massari, F. Giunchi, A. Altimari, C. Ciccarese, D. Bimbatti, A. Scarpa, R. Iacovelli, C. Porta, S. Virinder, G. Tortora, W. Artibani, R. Schiavina, A. Ardizzoni, M. Brunelli, S. Knuutila, G. Martignoni

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Renal cell cancer (RCC) is characterized by histological and molecular heterogeneity that may account for variable response to targeted therapies. We evaluated retrospectively with a next generation sequencing (NGS) approach using a pre-designed cancer panel the mutation burden of 32 lesions from 22 metastatic RCC patients treated with at least one tyrosine kinase or mTOR inhibitor. We identified mutations in the VHL, PTEN, JAK3, MET, ERBB4, APC, CDKN2A, FGFR3, EGFR, RB1, TP53 genes. Somatic alterations were correlated with response to therapy. Most mutations hit VHL1 (31,8%) followed by PTEN (13,6%), JAK3, FGFR and TP53 (9% each). Eight (36%) patients were wild-type at least for the genes included in the panel.A genotype concordance between primary RCC and its secondary lesion was found in 3/6 cases. Patients were treated with Sorafenib, Sunitinib and Temsirolimus with partial responses in 4 (18,2%) and disease stabilization in 7 (31,8%). Among the 4 partial responders, 1 (25%) was wild-type and 3 (75%) harbored different VHL1 variants. Among the 7 patients with disease stabilization 2 (29%) were wild-type, 2 (29%) PTEN mutated, and single patients (14% each) displayed mutations in VHL1, JAK3 and APC/CDKN2A. Among the 11 non-responders 7 (64%) were wild-type, 2 (18%) were p53 mutated and 2 (18%) VHL1 mutated.No significant associations were found among RCC histotype, mutation variants and response to therapies. In the absence of predictive biomarkers for metastatic RCC treatment, a NGS approach may address single patients to basket clinical trials according to actionable molecular specific alterations.
Original languageEnglish
Pages (from-to)7328-7335
Number of pages8
JournalOncotarget
Volume8
Issue number5
DOIs
Publication statusPublished - Jan 31 2017

Fingerprint

Renal Cell Carcinoma
Mutation
p53 Genes
Therapeutics
Protein-Tyrosine Kinases
Biomarkers
Genotype
Clinical Trials
Genes
Neoplasms

Keywords

  • Pathology Section
  • VHL
  • metastatic disease
  • next generation sequencing
  • renal cell carcinoma
  • target therapy

Cite this

Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. / Fiorentino, M.; Gruppioni, E.; Massari, F.; Giunchi, F.; Altimari, A.; Ciccarese, C.; Bimbatti, D.; Scarpa, A.; Iacovelli, R.; Porta, C.; Virinder, S.; Tortora, G.; Artibani, W.; Schiavina, R.; Ardizzoni, A.; Brunelli, M.; Knuutila, S.; Martignoni, G.

In: Oncotarget, Vol. 8, No. 5, 31.01.2017, p. 7328-7335.

Research output: Contribution to journalArticle

Fiorentino, M, Gruppioni, E, Massari, F, Giunchi, F, Altimari, A, Ciccarese, C, Bimbatti, D, Scarpa, A, Iacovelli, R, Porta, C, Virinder, S, Tortora, G, Artibani, W, Schiavina, R, Ardizzoni, A, Brunelli, M, Knuutila, S & Martignoni, G 2017, 'Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach', Oncotarget, vol. 8, no. 5, pp. 7328-7335. https://doi.org/10.18632/oncotarget.12551 [doi]
Fiorentino, M. ; Gruppioni, E. ; Massari, F. ; Giunchi, F. ; Altimari, A. ; Ciccarese, C. ; Bimbatti, D. ; Scarpa, A. ; Iacovelli, R. ; Porta, C. ; Virinder, S. ; Tortora, G. ; Artibani, W. ; Schiavina, R. ; Ardizzoni, A. ; Brunelli, M. ; Knuutila, S. ; Martignoni, G. / Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. In: Oncotarget. 2017 ; Vol. 8, No. 5. pp. 7328-7335.
@article{6eb971d0454e4a038b3d43e2b4121a3b,
title = "Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach",
abstract = "Renal cell cancer (RCC) is characterized by histological and molecular heterogeneity that may account for variable response to targeted therapies. We evaluated retrospectively with a next generation sequencing (NGS) approach using a pre-designed cancer panel the mutation burden of 32 lesions from 22 metastatic RCC patients treated with at least one tyrosine kinase or mTOR inhibitor. We identified mutations in the VHL, PTEN, JAK3, MET, ERBB4, APC, CDKN2A, FGFR3, EGFR, RB1, TP53 genes. Somatic alterations were correlated with response to therapy. Most mutations hit VHL1 (31,8{\%}) followed by PTEN (13,6{\%}), JAK3, FGFR and TP53 (9{\%} each). Eight (36{\%}) patients were wild-type at least for the genes included in the panel.A genotype concordance between primary RCC and its secondary lesion was found in 3/6 cases. Patients were treated with Sorafenib, Sunitinib and Temsirolimus with partial responses in 4 (18,2{\%}) and disease stabilization in 7 (31,8{\%}). Among the 4 partial responders, 1 (25{\%}) was wild-type and 3 (75{\%}) harbored different VHL1 variants. Among the 7 patients with disease stabilization 2 (29{\%}) were wild-type, 2 (29{\%}) PTEN mutated, and single patients (14{\%} each) displayed mutations in VHL1, JAK3 and APC/CDKN2A. Among the 11 non-responders 7 (64{\%}) were wild-type, 2 (18{\%}) were p53 mutated and 2 (18{\%}) VHL1 mutated.No significant associations were found among RCC histotype, mutation variants and response to therapies. In the absence of predictive biomarkers for metastatic RCC treatment, a NGS approach may address single patients to basket clinical trials according to actionable molecular specific alterations.",
keywords = "Pathology Section, VHL, metastatic disease, next generation sequencing, renal cell carcinoma, target therapy",
author = "M. Fiorentino and E. Gruppioni and F. Massari and F. Giunchi and A. Altimari and C. Ciccarese and D. Bimbatti and A. Scarpa and R. Iacovelli and C. Porta and S. Virinder and G. Tortora and W. Artibani and R. Schiavina and A. Ardizzoni and M. Brunelli and S. Knuutila and G. Martignoni",
note = "LR: 20170416; JID: 101532965; OTO: NOTNLM; 2016/07/06 00:00 [received]; 2016/09/21 00:00 [accepted]; 2016/10/16 06:00 [pubmed]; 2016/10/16 06:00 [medline]; 2016/10/15 06:00 [entrez]; ppublish",
year = "2017",
month = "1",
day = "31",
doi = "10.18632/oncotarget.12551 [doi]",
language = "English",
volume = "8",
pages = "7328--7335",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "5",

}

TY - JOUR

T1 - Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach

AU - Fiorentino, M.

AU - Gruppioni, E.

AU - Massari, F.

AU - Giunchi, F.

AU - Altimari, A.

AU - Ciccarese, C.

AU - Bimbatti, D.

AU - Scarpa, A.

AU - Iacovelli, R.

AU - Porta, C.

AU - Virinder, S.

AU - Tortora, G.

AU - Artibani, W.

AU - Schiavina, R.

AU - Ardizzoni, A.

AU - Brunelli, M.

AU - Knuutila, S.

AU - Martignoni, G.

N1 - LR: 20170416; JID: 101532965; OTO: NOTNLM; 2016/07/06 00:00 [received]; 2016/09/21 00:00 [accepted]; 2016/10/16 06:00 [pubmed]; 2016/10/16 06:00 [medline]; 2016/10/15 06:00 [entrez]; ppublish

PY - 2017/1/31

Y1 - 2017/1/31

N2 - Renal cell cancer (RCC) is characterized by histological and molecular heterogeneity that may account for variable response to targeted therapies. We evaluated retrospectively with a next generation sequencing (NGS) approach using a pre-designed cancer panel the mutation burden of 32 lesions from 22 metastatic RCC patients treated with at least one tyrosine kinase or mTOR inhibitor. We identified mutations in the VHL, PTEN, JAK3, MET, ERBB4, APC, CDKN2A, FGFR3, EGFR, RB1, TP53 genes. Somatic alterations were correlated with response to therapy. Most mutations hit VHL1 (31,8%) followed by PTEN (13,6%), JAK3, FGFR and TP53 (9% each). Eight (36%) patients were wild-type at least for the genes included in the panel.A genotype concordance between primary RCC and its secondary lesion was found in 3/6 cases. Patients were treated with Sorafenib, Sunitinib and Temsirolimus with partial responses in 4 (18,2%) and disease stabilization in 7 (31,8%). Among the 4 partial responders, 1 (25%) was wild-type and 3 (75%) harbored different VHL1 variants. Among the 7 patients with disease stabilization 2 (29%) were wild-type, 2 (29%) PTEN mutated, and single patients (14% each) displayed mutations in VHL1, JAK3 and APC/CDKN2A. Among the 11 non-responders 7 (64%) were wild-type, 2 (18%) were p53 mutated and 2 (18%) VHL1 mutated.No significant associations were found among RCC histotype, mutation variants and response to therapies. In the absence of predictive biomarkers for metastatic RCC treatment, a NGS approach may address single patients to basket clinical trials according to actionable molecular specific alterations.

AB - Renal cell cancer (RCC) is characterized by histological and molecular heterogeneity that may account for variable response to targeted therapies. We evaluated retrospectively with a next generation sequencing (NGS) approach using a pre-designed cancer panel the mutation burden of 32 lesions from 22 metastatic RCC patients treated with at least one tyrosine kinase or mTOR inhibitor. We identified mutations in the VHL, PTEN, JAK3, MET, ERBB4, APC, CDKN2A, FGFR3, EGFR, RB1, TP53 genes. Somatic alterations were correlated with response to therapy. Most mutations hit VHL1 (31,8%) followed by PTEN (13,6%), JAK3, FGFR and TP53 (9% each). Eight (36%) patients were wild-type at least for the genes included in the panel.A genotype concordance between primary RCC and its secondary lesion was found in 3/6 cases. Patients were treated with Sorafenib, Sunitinib and Temsirolimus with partial responses in 4 (18,2%) and disease stabilization in 7 (31,8%). Among the 4 partial responders, 1 (25%) was wild-type and 3 (75%) harbored different VHL1 variants. Among the 7 patients with disease stabilization 2 (29%) were wild-type, 2 (29%) PTEN mutated, and single patients (14% each) displayed mutations in VHL1, JAK3 and APC/CDKN2A. Among the 11 non-responders 7 (64%) were wild-type, 2 (18%) were p53 mutated and 2 (18%) VHL1 mutated.No significant associations were found among RCC histotype, mutation variants and response to therapies. In the absence of predictive biomarkers for metastatic RCC treatment, a NGS approach may address single patients to basket clinical trials according to actionable molecular specific alterations.

KW - Pathology Section

KW - VHL

KW - metastatic disease

KW - next generation sequencing

KW - renal cell carcinoma

KW - target therapy

U2 - 10.18632/oncotarget.12551 [doi]

DO - 10.18632/oncotarget.12551 [doi]

M3 - Article

VL - 8

SP - 7328

EP - 7335

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 5

ER -